Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab mechanism in psoriasis
NCT04541329Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tildrakizumab in plaque psoriasis, sponsored by University of California, San Francisco. Primary endpoint: Psoriasis Area and Severity Index at 3 months. Started Sep 2020; status: completed.
02
Drugs
tildrakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04541329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541329.